Science & Enterprise subscription

Follow us on Twitter

  • National Science Foundation is funding a new system that uses artificial intelligence to find optimal combinations… https://t.co/jbZAJqQpmT
    about 2 hours ago
  • New post on Science and Enterprise: NSF Funds AI Covid-19 Drug Combo Simulation https://t.co/j7DsIncCUk #Science #Business
    about 2 hours ago
  • A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for… https://t.co/CVwEr6dEoU
    about 2 hours ago
  • New post on Science and Enterprise: Gene-Edited Transplant Organ Company Raises $125M https://t.co/UYlUcA8Z5X #Science #Business
    about 6 hours ago
  • A home Covid-19 test is being evaluated with a smartphone app, as part of an NIH program to quickly develop Covid-1… https://t.co/82gYsU3rvr
    about 1 day ago

Please share Science & Enterprise

Gene-Edited Transplant Organ Company Raises $125M

Happy pig

A spin-off enterprise from academic labs is raising $125 million for genetically edited pigs to produce organs for human transplantation. . . . → Read More: Gene-Edited Transplant Organ Company Raises $125M

Synthetic RNA Start-Up Gains $80M in Early Funds

RNA strand illustration

A start-up company, spun off from a biomedical engineering lab at MIT, is raising $80 million for therapies made from synthetic circular RNA. . . . → Read More: Synthetic RNA Start-Up Gains $80M in Early Funds

Gene-Editing Biotech Acquires DNA Bar Code Company

DNA chip graphic

A developer of therapies using highly precise gene editing is acquiring a company delivering gene therapies identified with DNA bar codes. . . . → Read More: Gene-Editing Biotech Acquires DNA Bar Code Company

Infographic – Top Venture Investor in Each State

CB Insights compiled a list of the top technology venture investors in each state and D.C., and displayed the investors on a map. . . . → Read More: Infographic – Top Venture Investor in Each State

New Funds Backing Global Health, Early-Stage Ventures

Stock market graphic

Three new funds are financing start-up companies creating solutions for health issues in less-developed countries and early-stage life science businesses. . . . → Read More: New Funds Backing Global Health, Early-Stage Ventures

AI Cell Analysis Start-Up Raises $6M Seed Funds

T lymphocyte

A new enterprise using artificial intelligence to analyze individual cells for immune-related diagnostics and therapies is raising $6 million in seed funds. . . . → Read More: AI Cell Analysis Start-Up Raises $6M Seed Funds

AbbVie Licenses Engineered Crispr Cell Process

Drug maker AbbVie is acquiring a technology using the gene-editing process Crispr to produce new off-the-shelf engineered T-cells as disease therapies. . . . → Read More: AbbVie Licenses Engineered Crispr Cell Process

New Venture Fund Backs Underserved, Academic Start-Ups

Investor screen

A new $300 million venture capital fund is underway that aims to support technology start-ups often left behind by larger mainstream investors. . . . → Read More: New Venture Fund Backs Underserved, Academic Start-Ups

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

Cannabidiol Drug Maker Acquired in $7.2B Deal

Cannabis plant

A developer of treatments for rare neurological diseases derived from cannabis is being acquired by Jazz Pharmaceuticals in a $7.2 billion deal. . . . → Read More: Cannabidiol Drug Maker Acquired in $7.2B Deal